All results / Stories / Joel Russell


Amgen Seeks New Monthly Dosage for Repatha

Amgen Inc. has submitted an application for regulatory approval of a new single-dose syringe for cholesterol drug Repatha, the company announced Friday.

Afrezza for Sale in U.S.

MannKind Corp. announced on Tuesday that its Afrezza brand of inhalable insulin is now available by prescription at U.S. pharmacies.

FDA Approves Amgen Cholesterol Drug Repatha

Amgen Inc. has received approval to market its cholesterol drug Repatha in the United States.

Study Could Boost Medtronic Insulin Pump Sales

Medical Devices: Better blood-sugar control found among Type 2 pump users.

A new study shows that Medtronic Inc. insulin pumps achieve better blood sugar control than multiple daily insulin injections for Type 2 diabetics – a conclusion that should help the device gain further market penetration.

Amgen Gains on Drug Study

Amgen Inc. announced on Monday positive human trial results for a cancer drug that was the focus of a multibillion dollar acquisition last year.

City, County Officials Seek Answers About Aliso Canyon

Los Angeles City and county officials have submitted motions endorsing a state legislative bill to prohibit gas injection at Aliso Canyon until the last year’s leak is explained.

Caruso Changes Name

Caruso Affiliated, the development company behind the shopping centers Americana at Brand in Glendale and Commons at Calabasas, has changed its name to simply Caruso.

Update: FDA Panel Recommends Afrezza Approval

Shares of MannKind Corp. more than doubled in after-hours trading on Tuesday after an FDA advisory panel recommended the agency approve the Valencia company's Afrezza insulin inhaler.

Capstone to Partner on Plasma Technology

Capstone Turbine Corp. has partnered with FGC Plasma Solutions to test a new plasma-assisted fuel injection technology for its C65 microturbines.

FDA Could Limit MannKind Insulin Inhaler

Shares of MannKind Corp. fell 7 percent on Friday after the FDA staff raised safety questions about the company’s inhalable insulin device, which could limit its use for certain patients.

Amgen Drug Study Disappoints

An injectable heart drug licensed to Amgen Inc. failed to perform in a clinical study, but the company plans to await further test results before deciding whether to continue or abandon development of the drug.

Amgen Seeking Cholesterol Drug Approval

Amgen Inc. announced on Thursday that it will seek U.S. government approval to sell pipeline drug evolocumab that has significantly reduced cholesterol for patients in clinical trials.

Kythera Acquired for $2.1 Billion

Kythera Biopharmaceuticals, Inc. will be acquired by Allergan plc in a $2.1 billion buyout announced Wednesday.

Insulin Pump Pact Boosts Medtronic Division

Health Care: Aetna links up with Northridge unit to study effects of treatment.

Aetna Inc. and Medtronic Inc. have embarked on a two-year collaboration to help diabetics adopt insulin pumps.

Tease photo

FDA Delay Drops MannKind Shares

Shares of MannKind Corp. fell nearly 8 percent Monday after the company announced that the FDA’s final decision on its inhalable insulin could be delayed beyond an expected April 15 deadline.

Investors See Double Over Chin Drug

Biotech: Kythera reaches milestone as FDA to review anti-fat compound.

Biotech: A drug that can dissolve fat has inspired shareholders to back Kythera Biopharmaceuticals.

Fat-Burning Drug Moving to Sales Slow Lane

MARKETING: Firm behind Kybella to hold off on consumer ads for now.

Kythera Biopharmaceuticals Inc. has one of the hottest new biotech drugs around: an injectable that has been shown to markedly reduce skin fat.

Putting Quick Back in the Urgent Care Concept

Health Care: Northridge clinic works out deal to see business employees faster.

In a health care system where even a slight injury or sickness can wipe out an entire workday, Dr. Bardia Anvar decided to find a way to recoup some of that lost productivity.

Amgen, Merck Expand Cancer Research Pact

Amgen Inc. will expand its collaboration with Merck on research seeking a cure for a special type of head and neck cancer, the company announced Friday.

Kythera Drug Wins FDA Approval

A fat-dissolving drug from Kythera Biopharmaceuticals Inc. that reduces double chins was approved by the Food and Drug Administration Wednesday.